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ABSTRACT 
 
The prevalence of gallstone disease in the world is 10-20%. Almost 20% of those with 
gallstone disease develop a complication during their lifetime. Acute cholecystitis (AC) is a 
common complication of gallstones, that is routinely managed with cholecystectomy. 
Technical developments have made it possible to use a minimally invasive laparoscopic 
technique for removing the gallbladder and stones. The postoperative complication rate, 
although seen after only a minority of procedures, is important due to the large number of 
cholecystectomies performed annually. The complication rate is lower in healthy patients 
and when the procedure is performed electively. The infectious complication rate may, 
however, reach 17% if surgery is performed for mild to moderately severe AC. 
Use of antibiotic prophylaxis (AP) has been firmly established as routine practice despite 
the lack of international guideline recommendations. There are many studies on low-risk 
patients showing minor or no impact of preoperative antibiotic prophylaxis (PAP) on 
postoperative infectious complications (PIC). Prior to this thesis, the benefit of AP in acute 
laparoscopic cholecystectomy (Lap-C) had not been studied.  
 
The aim of Study I was to explore the impact of AP on PIC in AC. In Study II the use of 
AP in Sweden was plotted at three different levels; county, hospital and surgeon. Study III 
aimed at exploring the impact of comorbidity on the risk for PIC. Study IV was a 
randomised controlled trial assessing the effectiveness of AP in reducing PIC. 
 
For the population-based cohort studies (I – III), we used Swedish Registry for Gallstone 
Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks) and the 
National patient register (NPR) as sources of data. Study IV was conducted as a double-
blinded randomised study between 2009 and 2017.  
 
Study I showed that there was no benefit of AP on PIC in acute cholecystectomy due to 
AC, even when adjusting for the most relevant confounders. Study II showed that AP usage 
differed between hospitals and surgeons, but not between counties. The difference was not 
related to the degree of inflammation or procedure difficulty. Study III explored patient-
related risk factors. The risk for surgical site infection was increased in patients with 
connective tissue disease, diabetes, chronic kidney disease, cirrhosis and obesity. There was 
also a significantly higher risk for septicaemia in patients with chronic kidney disease or 
cirrhosis. In Study IV, there was no difference in the rate of PIC and bactibilia between the 
group receiving AP and those receiving placebo. Raised CRP and operation method were 
significantly associated with PIC.  
 
PIC is multifactorial and single dose AP preoperatively has no more than an additive effect 
on PIC. Patient-related risk factors should, however, be taken into consideration when 
deciding on AP. International guidelines based on well-designed studies are urgently 
needed so that the decision to administer AP during acute cholecystectomy for AC becomes 
more stringent and uniform. 
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1 INTRODUCTION 
 
1.1 HISTORICAL BACKGROUND 
The first surgical management of gallbladder disease was accidentally undertaken when Jean-
Louis Petit (1674-1750), a Parisian surgeon, in 1743 incised an abdominal wall lesion that 
turned out to be the inflamed gallbladder firmly adherent to the abdominal wall (1). He thus 
became the first to describe a cholecystostomy. In 1867 Dr J. Bobbs performed surgery on a 
patient for a mass presumed to originate from the ovarium, which however turned out to be 
an enlarged stone-filled gallbladder. Cholecystostomy was later performed by Sims, Kocher 
and Tait in the succeeding decade. It was not until 1882, however, that Langenbuch, a 
German surgeon, performed the first cholecystectomy at Lazarus Hospital in Kiel, Germany. 
The procedure was successfully performed on a 43-year-old patient with chronic 
cholecystitis, biliary colic and morphine addiction. By 1897, he had performed 100 
cholecystectomies with a mortality rate of about 20%.  In 1985, almost one century later, 
technical developments made it possible for Erich Mühe, also from Kiel, to perform the first 
laparoscopic cholecystectomy (Lap-C) (2). 
 
 
Figure 1: Overview image of trunk anatomy. Illustration by FB Scientific Art Design, Fuad 
Bahram. 
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1.2 PREVALENCE 
Gallstone disease has afflicted humans since long time, and gallstone have been found at 
autopsy on Egyptian (3) and Chinese mummies (4). 
The overall prevalence of gallstones worldwide is 10-20%, and about 10 % in the Western 
world (5). The formation of gallstone disease is multifactorial as witnessed by prevalence 
figures that vary between different ethnical populations as well as between countries. It is 
inordinately high amongst American natives and lowest in black Africans (6, 7). More than 
80 % of people with gallstones are asymptomatic and their disease clinically silent (5, 7). The 
cumulative rate of biliary complication in asymptomatic stone disease is about 3% over 10 
years, while 1-3% of those with symptomatic gallstone disease develop acute cholecystitis 
(AC) each year following diagnosis (5, 6). In Scandinavia, 50% of those eventually treated 
for gallstones developed their disease by the age of 50 (6). 
1.3 PATHOGENESIS 
The three principal factors involved in the formation of cholesterol gallstone are cholesterol 
supersaturation, nucleation and hypomotility of the gallbladder (6). There are two main types 
of gallstones; cholesterol gallstones, containing more than 50% cholesterol (75-80% of 
gallstones in the Western world), and pigment stones. Pigment stones may further be divided 
into black (10-15%), and brown (5-10%) that contain 30% cholesterol. Bacterial colonisation 
is involved in the formation of pigment gallstones (3) and black gallstones are the result of 
increased production of unconjugated bilirubin that forms the stone (6). Ethnicity plays an 
important role in stone formation; cholesterol gallstones being more common in developed 
countries in the Western world, while brown pigment stones are more common in Asia (7).  
 
 
Figure 2: Gallstone in the gallbladder and bile duct anatomy. Illustration by FB Scientific 
Art Design, Fuad Bahram. 
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Risk factors for gallstone formation are many, some being modifiable: 
1.3.1 Age 
Age is a well-known risk factor, which may be explained by the fact that cholesterol secretion 
into the bile increases with age. 
1.3.2 Gender 
The prevalence of gallstone disease differs between younger men and women but this 
difference declines in the elderly (7, 8). In general, gallstones are approximately twice as 
common in women as in men. In many studies, the prevalence has been found to be as much 
as three times higher in women. However, after the fifth decade the prevalence differs little 
between men and women, which may be explained by the fact that the oestrogen levels in 
women decrease (6). In Europe, the rate is 18.8% for women and 9.5% for men (6). In the 
USA, the corresponding rates are 16.6% and 8.6% (7). Changes in prevalence with age in 
women is probably related to the influence of female hormones. Oestrogen increases 
cholesterol secretion and decreases bile salt secretion, while progestin decreases bile salt 
secretion and lessens gallbladder emptying (7).  
1.3.3 Obesity 
Genetic predisposition to gallstone disease is not fully understood, but there is undoubtedly a 
strong genetic influence (6). 
1.3.4 Total parenteral nutrition (TPN) and rapid weight loss 
TPN is associated with acalculous cholecystitis, cholelithiasis and cholecystitis. The 
pathogenesis behind the association between total parenteral nutrition and gallstones may be 
gallbladder hypomotility with bile stasis due to prolonged periods without enteral nutrition 
(6). Biliary sludge has been seen in patients after 5-10 days who did not receive enteral 
nutrition on the intensive care unit (7). The sludge usually dissolves within 4 weeks of TPN 
discontinuation (7). Similar pattern has been seen in pregnancy and in rapid weight loss. 
Rapid weight loss is associated with gallstone formation in 30-71%, the association has been 
seen in persons with weight loss ≥1.5 kg/ week (7). The assumed pathogenesis is a change in 
cholesterol metabolism and increase of cholesterol concentration in the bile that promotes 
stone formation (9). 
1.3.5 Pregnancy 
Gallstone formation in pregnant women is caused by increased oestrogen levels, increased 
cholesterol secretion, and decreased motility of the gallbladder due to increased progesterone 
levels (6). The stone usually dissolve after delivery (7). 
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1.3.6 Other risk factors 
Drugs, liver disease, Crohn’s disease, cystic fibrosis, chronic kidney disease, sickle cell 
disease, chronic haemolysis, spinal cord injury, increased cholesterol intake, dyslipidaemia 
and insulin-resistant diabetes may all promote gallstone formation (3, 6, 7, 10). 
 
1.4 GALLSTONE DISEASES COMPLICATIONS 
Cholecystitis is one of the most common complications of gallstone disease. AC is most often 
caused by gallstones, i.e. acute calculous cholecystitis (ACC). Biliary duct obstruction due to 
an impacted gallstone with associated bile stasis is the initial step in the development of AC. 
Increased and sustained intraluminal pressure in the gallbladder impairs mucosal blood flow 
and leads to ischaemia. Chemical mediators such as Lysolecithin are released within the 
stagnant bile, causing ischaemic damage to the mucosa. This leads to chemical cholecystitis 
with accumulation of inflammatory infiltration and oedema of the gallbladder wall. Once 
inflammation of the gallbladder begins, further inflammatory mediators are released; the most 
important being prostaglandin, which is involved in gallbladder contraction and fluid 
absorption.  Secondary bacterial infection of the bile may subsequently occur in patients with 
ACC (Fig 3) (5, 11). 
 
 
Figure 3: Pathogenesis of acute calculous cholecystitis. Illustration by FB Scientific Art 
Design, Fuad Bahram. 
AC is a common clinical problem accounting for up to 5% of visits to the emergency 
department (11), and 9% or the third major cause of hospital admissions (11, 12).  
Almost 30% of patients who do not undergo surgery after ACC suffer a new event (biliary 
colic, bile duct obstruction or pancreatitis) within a year (8).
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1.5 DIAGNOSTIC CRITERIA 
Diagnostic criteria commonly used are the Tokyo Guidelines 13 (TG13) criteria; a revised 
form of the TG07 diagnostic criteria.  They include the following:  
A. Local signs of inflammation (Murphy’s sign / Right Upper Quadrant [RUQ] 
mass/pain/tenderness). 
B. Systemic signs of inflammation (fever, elevated C-Reactive Peptide [CRP], elevated 
White Blood Cell count [WBC]).   
C. Imaging findings characteristic of AC.  
According to the TG13, AC should be suspected if at least 1 item in A + 1 item in B are 
positive. The AC diagnosis is definite if 1 item in A, 1 item in B, and C are positive. This 
definition has a sensitivity of 91.2% and a specificity of 96.9 % (13). There are, however, 
studies showing a sensitivity of only 53% in the diagnosis of AC (14). A detailed medical 
history, careful clinical examination, laboratory test results and imaging may indicate AC 
more accurately (8).   
1.5.1 Clinical indicators 
There is no single clinical or laboratory finding with sufficient diagnostic accuracy to confirm 
or exclude AC (8). Since Murphy’s sign was described as a sign of cholecystitis in 1903, it 
has been widely recognised as part of the clinical examination, but it has low sensitivity albeit 
a high specificity (13). RUQ pain and tenderness are more frequent in patients with AC than 
are Murphy’s sign and a RUQ mass (14). 
1.5.2 Radiologic imaging 
Abdominal ultrasonography (AUS) is the investigation of choice and primary imaging 
technique for ACC (5, 8) even though it only has a sensitivity of 81% and a specificity of 
83% in detecting cholecystitis (15). The reason is its low cost, availability, lack of 
invasiveness and high accuracy regarding stones in the gallbladder (8). Stones and 
inflammatory changes in the gallbladder wall on AUS or during surgery are criteria for 
diagnosing ACC. The TG18 criteria for ACC are: thickening of the gallbladder wall (≥4 
mm); enlargement of the gallbladder (long axis ≥8 cm, short axis ≥4 cm); gallstones or 
retained debris; pericholecystic fluid accumulation; linear shadows in the fatty tissue around 
the gallbladder (15); and direct tenderness when the probe is pushed against the gallbladder 
(sonographic Murphy’s sign) (13). 
Computer tomography has a relatively low sensitivity and specificity when diagnosing ACC. 
There is insufficient data available to support magnetic resonance imaging (MRI), which has 
the same sensitivity and specificity as AUS. Although cholescintigraphy (hepatobiliary 
iminodiacetic acid scan) has a sensitivity of 95% and specificity 90%, its availability, the time 
required to perform the test, and exposure to ionizing radiation limit its use (8). 
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1.6 GRADING AND SEVERITY OF CHOLECYSTITIS 
In 2007, severity assessment criteria for AC were presented in Tokyo Guidelines 2007 
(TG07). AC was graded from I to III, where Grade I is cholecystitis without any organ 
dysfunction and mild disease of the gallbladder. Grade II is moderate AC, where the degree 
of acute inflammation is likely to be associated with increased difficulty in performing 
cholecystectomy. Grade III is defined as AC associated with organ dysfunction (Table 1) 
(13). 
Several studies have validated TG13 severity grading and concluded that it has a high 
predictive value for 30-day mortality, length of hospital stay, conversion rate and medical 
costs. Even bile duct injury and postoperative pathological findings of gangrenous and 
emphysematous cholecystitis are significantly higher in higher grade cases (15). 
However, the TG13classification of AC does not include the risk stratification scores most 
adopted, lacks clinical validation, and has no prognostic value regarding surgical risk, and 
does not improve outcome (8). 
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Grade I (mild) acute cholecystitis 
Does not meet the criteria of ‘‘Grade III’’ or ‘‘Grade III’’ acute cholecystitis. Grade I 
can also be defined as acute cholecystitis in a healthy patient with no organ dysfunction 
and mild inflammatory changes in the gallbladder, making cholecystectomy a safe and 
low-risk operative procedure. 
Grade II (moderate) acute cholecystitis associated with any one of the following 
conditions:  
1. Elevated white blood cell count (>18,000/mm3).  
2. Palpable tender mass in the right upper abdominal quadrant.  
3. Duration of complaints >72 h.  
4. Marked local inflammation (gangrenous cholecystitis, pericholecystic abscess, hepatic 
abscess, biliary peritonitis, emphysematous cholecystitis).  
Grade III (severe) acute cholecystitis associated with dysfunction of any one of the 
following organs/systems:  
1. Cardiovascular dysfunction: Hypotension requiring treatment.  
2. Neurological dysfunction: Decreased level of consciousness.  
 3. Respiratory dysfunction: PaO2/FiO2. 
4. Renal dysfunction: Oliguria, creatinine >2.0 mg/dl.  
5. Hepatic dysfunction: PT-INR (1.5).  
6. Haematological dysfunction: Platelet count/100,000/mm3. 
Table 1: Severity grading of AC according to TG13 (13).  
 
1.7 MANAGEMENT 
Management of AC has evolved over time, from the treatment of inflammation with 
antibiotics and elective open cholecystectomy after 4-6 weeks, to early open 
cholecystectomy, and finally to Lap-C. Lap-C was initially recommended for elective 
surgery, but there has recently been a trend towards acute Lap-C (11). 
Several studies have shown that surgery is superior to observation. In a population-based 
longitudinal study of patients managed with a conservative approach and followed for 7 years 
in Canada, almost 30% had a gallstone-related event within a year most of these being in the 
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18-34 age-group (8). An RCT study in UK found that symptomatic but uncomplicated 
cholecystitis managed conservatively was associated with a higher rate of complications 
(14% compared to 2% with intervention) (8).  Cholecystectomy for Grade I AC is considered 
a safe low-risk procedure (13). In a review from 2008, cholecystectomy for Grade III 
cholecystitis was not associated with an increase in local postoperative complications despite 
a three times higher conversion rate. Based on these findings, the authors concluded that 
severe cholecystitis is an acceptable indication for Lap-C (16). Surgery compared to 
conservative treatment in the management of high-risk patients has not been so well 
investigated (11). 
Percutaneous cholecystostomy (PC), i.e. gallbladder drainage with decompression and 
removal of infected bile and pus, is a potential alternative to cholecystectomy in high-risk 
patients. This enables conversion of a septic patient with cholecystitis into a non-septic 
condition. It has a low procedure-related mortality rate (0.36%) though the 30-day mortality 
is high (15.4%) (8) up to 36% in other studies (17). Of patients with severe AC undergoing 
PC during the acute admission, 60-80% did not undergo cholecystectomy at a later stage (11). 
PC had no beneficial effect on surgical outcomes such as duration of surgery, hospital stay, 
and mortality rate (18). 
Surgical removal of gallstones in ACC is not routine. However, in 2013 Young et al 
published 316 consecutive laparoscopic gallbladder-preserving cholelithotomy procedures, 
where the recurrence rate was 15%. Since the gallbladder is dysfunctional in the acute setting, 
this is not an alternative for treating ACC (8). 
Initial management, including fasting, intravenous fluid and antibiotics, has gained 
consensus, though not supported by well-designed studies. This approach has been accepted 
worldwide and is recognised by the Tokyo Guidelines 2018 (TG18) (18). Even the Surgical 
Infection Society and the Infectious Diseases Society of America recommend intravenous 
antibiotic treatment (18). Despite the high rate of ACC, this recommendation had not been 
tested scientifically before (12). 
The role of ursodeoxycholic acid in the treatment of cholecystitis was studied in a large 
randomised, double-blind, placebo-controlled trial in patients waiting for elective 
cholecystectomy for biliary colic, and found to be ineffective (19). It has been shown to 
significantly decrease the risk for cholelithiasis after sleeve gastrectomy in patient with 
morbid obesity (20). Other non-surgical methods such as extra-corporeal shock wave 
lithotripsy (ESWL) in non-inflamed gallbladder disease, have been tested. The rate of 
recurrence after ESWL was 30 to 50 % after a 5-year follow-up (8). 
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1.8 SURGICAL APPROACH (LAPAROSCOPIC OR OPEN 
SURGERY) 
The majority of cholecystectomies for ACC (71-95.8 %) begin with a laparoscopic approach.  
This includes a large number of procedures converted to an open procedure due to technical 
or anatomical difficulties (Fig 4) (18). 
Two randomised studies and one population-based cohort study have been published, 
demonstrating that Lap-C is associated with faster recovery, shorter hospital stay, and lower 
mortality and morbidity rates compared to open cholecystectomy (21, 22). This also applies 
to the elderly population (23). The TG13 recommended that Lap-C be limited to the mildest 
forms of AC (21). In 2018 this recommendation was modified to state that Grades I–III 
cholecystitis are eligible for Lap-C depending on the patient’s Charlson Comorbidity Index 
(CCI) score and American Society of Anaesthesiologists physical status classification (ASA) 
(18). Contrary to TG13, the WSES and EAES recommend Lap-C even for severe 
cholecystitis, based on the results of a meta-analysis (21). However, the TG 18 do not use 
POSSUM and APACHE II, which are superior to ASA in risk prediction (8). In cases where 
Lap-C is not possible, TG18 recommend a conservative approach including PC in Grades II-
III cholecystitis (18). 
 
 
Figure 4: Laparoscopic versus open cholecystectomy.. Illustration by FB Scientific Art 
Design, Fuad Bahram. 
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In a few poorly designed RCTs on heterogeneous study groups, Lap-C has been shown to 
result in shorter duration of surgery, lower overall incidence of postoperative complications, 
lower in-hospital morbidity and mortality, fewer infectious complications, and shorter 
hospital stay compared to open cholecystectomy (24, 25). Lap-C is the method of choice even 
in high-risk patients with cirrhosis Child Grades A and B (8, 26, 27). The same applies for 
those aged 80 years and over (8, 21) and pregnant women, but not in cases where there is 
absolute contraindication to anaesthesia or septic shock (8).  
Robot-assisted cholecystectomy has been tried in experiment procedures, with a similar 
complication rate and duration of surgery as Lap-C (28). 
 
1.9 TIMING 
Despite the relative frequency of ACC, historically there has always been controversy about 
the timing of surgery (8). The initial “golden” 72–hour period after admission has been 
proposed as an appropriate window in which to perform Lap-C. After that, the risk for 
complications and conversion rate to open procedure increase (29). 
A population-based study showed no significant association between preoperative symptom 
duration and 30-day mortality, but an association with longer operation time and higher 
conversion rate to open cholecystectomy. Based on these results, the European Association of 
Endoscopic Surgery (EAES) recommends Lap-C as soon as possible after the onset of 
symptoms of AC (21). 
A meta-analysis of case-control studies including over 40,000 patients showed that the 
mortality rate (0.57%) was lower after early Lap-C than after delayed (72 hours-7 days and 
>7 days or >4 weeks and <4 weeks). The overall complication rate was 8% in the early Lap-
C groups and 11.5% in the delayed groups, where differences were significant comparing 
<72 with >72 hours or < 7 days with < 4 weeks, but not significant when comparing <72 
hours with >4 weeks or <7 days with >4 weeks. The risk for bile duct injury was significantly 
lower in operations performed <7 days compared to >4 weeks, almost reached significance 
comparing <7 days with <4 weeks and <72 with >72 hours, but was not significant when 
comparing <72 hours with>4 weeks. Wound infection and conversion rates were significantly 
lower and length of hospital stay significantly shorter in the early group compared to the 
delayed group. The authors recommended early Lap-C even if more than 72 hours have 
passed, and stated that this should be standard care in the management of AC. Even from the 
point of view of bile duct injury and postoperative bile leakage, Lap-C should be performed 
after 72 hours since it is not associated with increased risk. A weakness of this meta-analysis 
is that selection bias, i.e. straightforward procedures in the early Lap-C groups and more 
complicated in the delayed groups, could not be ruled out (29). 
Several randomised controlled trials and meta-analyses have shown advantages of early 
cholecystectomy in terms of total hospital stay, complications and conversion rates (21).  
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In a meta-analysis of 15 RCTs comparing early (72 hours-1 week) with delayed (at least > 6 
weeks) cholecystectomy, early surgery resulted in shorter hospital stay and lower overall 
cost. There was no difference in mortality rate, complication rate or bile duct injury rate. 
However, tissues were seen to become progressively more scarred after repeated episodes of 
inflammation, making surgery more difficult (18). 
The World Society of Emergency Surgery (WSES) recommends early cholecystectomy if the 
onset of the symptoms is less than 10 days prior to admission, since the complication or 
conversion rates are not higher and the total hospital stay is shorter. If patients with symptoms 
> 10 days develop peritonitis or sepsis, emergency surgical intervention may become 
necessary. Otherwise, cholecystectomy delayed for 45 days is preferable (8). 
 
1.10 MICROBIAL PATTERN 
The inflammatory process in cholecystitis is initially sterile. However, bactibilia develops in 
9-72 % of cases (8, 12). In studies from the last two decades it ranges from 7.7% to 15.8% 
(30). Escherichia coli, Enterobacter, Klebsiella and Enterococcus species are the most 
commonly identified organisms in patients with AC (11). 
Intra-abdominal microbiological cultures obtained from 306 patients with severe cholecystitis 
and sepsis showed that 7.8 % had resistant bacteria. Almost ten per cent of gram-negative 
strains and 4.6% of gram-positive strains were found to be resistant. Presence of resistant 
bacteria was associated with nosocomial infection, inadequate antimicrobial therapy and 
recent antimicrobial therapy (31). 
The TG18 recommend that bile should be obtained for culture at the beginning of all 
procedures performed for AC Grades II and III (Level 1 recommendation) (30). Bactibilia 
was found not to be a predictive risk factor for the development of wound infection; it is, 
however, associated with postoperative mortality and morbidity (32). 
There is a higher probability of finding positive bile cultures in AC with a common bile duct 
stone than in chronic cholecystitis without a common bile duct stone. In a study on 84 
patients undergoing elective cholecystectomy, no positive bile culture was found in any of the 
gallbladders with a normal wall or in those with cholesterolosis (33). 
 
1.11  POSTOPERATIVE COMPLICATIONS  
The overall postoperative complication rate after planned cholecystectomy ranges from 1 % 
to 11 %. However, the rate is higher after AC; reaching 20 % in some hospitals (34). The 
postoperative infectious complication rate (PIC) during admission is approximately 11% 
(32). 
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Risk factor for postoperative complications: 
1.11.1 Severity grade of inflammation 
 The mortality rate of patients with cholecystitis is approximately 1%; 1.1% with Grade I and 
5.4% with Grades II-III (35).  
The risk for more serious complications (higher than Grade II on the Clavien-Dindo 
postoperative complication scale) is higher in Grade III cholecystitis (15). 
1.11.2 Comorbidity 
The TG18 identify neurological and respiratory dysfunction and coexistence of jaundice as 
negative predictive factors in Grade III AC, with a statistically significant increase in 30-day 
postoperative mortality rate (18). Diabetes is another risk factor that increases the mortality 
risk with an adjusted odds ratio (OR) of 1.79. Furthermore, delayed surgery in patients with 
diabetes is associated with a significantly higher risk for developing surgical site infection 
(SSI) and a longer hospital stay (8). Cardiovascular event and renal failure were associated 
with adjusted ORs of 2.5 and 3.9, respectively (8), but according to TG18 renal and 
cardiovascular dysfunction are not negative predictive factors (18). 
Cirrhosis remains the major risk factor for surgery. In a population-based study using data 
from the Swedish Register for Gallstone Surgery and endoscopic retrograde 
cholangiopancreatography (GallRiks) between 2006 and 2011, the postoperative 
complication rate in cirrhotic patients was 16.9% compared to 9.2% in non-cirrhotic patients 
(36). Lap-C in patients with liver cirrhosis is associated with significantly longer operation 
time, increased blood loss, increased conversion rate, longer hospital stay and increased 
overall morbidity and mortality rates compared to non-cirrhotic (8). 
1.11.3 Age 
Age older than 80 years, even patients with ASA I-II, has been shown to be associated with a 
significantly higher mortality rate (30 % compared to 5.5 % for age group 65-79 years and 
1% for age group 50-64 years). With higher ASA Classes (III and IV) or urgent 
cholecystectomy, the mortality rates increase to 76 %, 25.6 % and 29 % respectively (8). 
 
1.12 ANTIBIOTIC TREATMENT 
There is substantial evidence that the selective use of antibiotic prophylaxis (AP) in high-risk 
surgical procedures reduces PIC and decreases the overall use of antibiotics, which in turn 
reduces the risk of resistance. There is, however, no scientific basis for using AP in gallstone 
surgery if there are no specific patient or procedure risk factors.  What is meant by 
“postoperative infectious complication” needs to be defined more clearly and registration of 
this outcome should be done after sufficiently long follow-up if we are to develop better 
evidence-based routines (37).  
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WSES favours antibiotic treatment in all case of ACC, even though the recurrence rate is 
high (8). Antibiotic resistance is one of the greatest threats to global health and it is related to 
longer hospital stays, higher costs and increase in mortality (38). Inappropriate antibiotic use 
increases medical costs. Furthermore, long-term antibiotic misuse leads to increase in the 
isolation of drug-resistant bacteria, difficulty in treating infectious diseases, and the spread of 
multiple-resistant bacteria within hospitals (39). Overuse or inappropriate antibiotic use not 
only increases bacterial resistance and makes treatment more difficult; it also severely 
threatens medical quality and safety (39). Careful choice of antibiotics, good timing of 
administration, proper supplementary antimicrobial treatment, and a high pathogen detection 
rate enhance the chances of successful treatment, and thus reduce the use of unnecessary 
antibiotics. Furthermore, this reduces SSI and the development of bacterial resistance (39). 
A randomised study comparing intravenous antibiotic treatment with placebo in mild ACC 
according to the TG grading system at index admission and treated by elective Lap-C, 
showed that there was no significant difference in the length of hospital stay, readmission, 
positive bile culture or postoperative complication rate (bleeding or need for ERCP) (12). 
The use of antibiotics varies greatly between clinicians, indicating a lack of evidence-based 
guidelines. Many clinicians advocate routine administration of antibiotics to all patients 
diagnosed with AC, whereas others restrict antibiotic treatment to patients likely to develop 
sepsis based on clinical, laboratory, and imaging findings (8). 
Because of the development of bactibilia in up to two-thirds of AC cases, it is still 
recommended that antibiotics covering gram-negative bacteria and anaerobes are routinely 
administered to all patients diagnosed with AC, and continued until clinical resolution or 
cholecystectomy (11), despite the fact that there is no correlation between bactibilia and 
overall outcome (17). 
1.12.1 Preoperative antibiotic prophylaxis (PAP) 
 The Janusinfo recommendation is to give 1-2 doses AP immediately prior to acute 
cholecystectomy and a second dose if the duration of surgery exceeds 3 hours, and no AP in 
elective cholecystectomy. The choice of the antibiotic is trimethoprim-sulfamethoxazole 10 
ml iv, or doxycycline 200 mg iv or cefuroxime 1,5 g iv, or cefotaxime 1 g iv. In the case of 
Type 1 allergy to penicillin or cephalosporin, clindamycin 600 mg intravenous may be given 
(40). 
Based on TG18 recommendations, mild cholecystitis (Grade I) should not be treated, or 
treated with a first-generation cephalosporin (oral or iv) without any further explanation. 
Moderate cholecystitis (Grade II) should be treated with a wider-spectrum penicillin or 
second-generation cephalosporin, and for severe cholecystitis (Grade III) a third or fourth-
generation cephalosporin, or a carbapenem, plus metronidazole should be used (30). The 
TG18 recommend antimicrobial prophylaxis based on the results of a study from 2007 (41), 
which was consensus- and in vitro activity-based, not RCT studies (30). 
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Many studies and meta-analyses have reported no benefit of AP in elective laparoscopic 
cholecystectomy (42). 
It has been suggested that AP should be given to patients with a high risk of having bactibilia, 
i.e. in those aged >60 years, and those with fever, leucocytosis or hyperbilirubinemia 
(advanced cholecystitis and/ cholangitis) (32). 
1.12.2 Postoperative antibiotic prophylaxis 
It was not until the late 1980’s that surgeons began to accept the surgical procedure per se to 
be the most critical factor in predicting SSI. In1985, Haley and colleagues investigated 
factors related to SSI, and confirmed the great impact of surgical performance. Single-dose 
AP is now recommended in clean surgical procedures where foreign body material is used 
and in clean-contaminated procedures. If the procedure lasts more than 2-3 hours, the dose is 
repeated (43). 
Two RCTs on postoperative antibiotic treatment in Grades I and II cholecystitis showed that 
placebo is not inferior to treatment (44, 45). In another two RCTs on placebo versus 
postoperative antibiotic treatment showed no difference in PIC or other morbidity rates (46, 
47). 
The TG18 recommends discontinuation antimicrobial therapy within 24 hours after 
cholecystectomy performed for community-acquired Grades I and II cholecystitis. If 
perforation, emphysematous changes, or necrosis of the gallbladder are encountered during 
surgery, antibiotic treatment over 4-7 days is recommended. In cholecystitis Grade III, 
antibiotics should be given 4-7 days after the source of infection has been controlled, and if 
bacteraemia with gram-positive cocci (Enterococcus spp., Streptococcus spp.) is found, then 
antibiotics should be given a minimum duration of 2 weeks (30). In a prospective study, it 
was seen that surgeons commonly prolong postoperative antibiotic treatment in the elderly 
and if bile spillage occurs (32). 
On the other hand, the WSES does not advocate postoperative antibiotic treatment in 
uncomplicated ACC (Grades I and II). In complicated cases, the antimicrobial regimen 
depends on the pathogens assumed to be involved and the risk of major resistance patterns. If 
used, antibiotics must have good bile penetration (bile/serum concentration ratio >1) e.g. 
piperacillin/tazobactam with penetration efficiency of 4.8, or ciprofloxacin or a penicillin >5. 
According to the WSES recommendation, there are 5 lines of treatment in community-
acquired ACC: 
A. Beta-lactam inhibitor combination-based regimens - amoxicillin/clavulanate in the 
stable patient and piperacillin/tazobactam in the unstable patient;  
B. Cephalosporin-based regimens - third and fourth generation cephalosporin in 
combination with metronidazole (in stable patients); 
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C. Carbapenem-based regimens - ertapenem in stabile patients and imipenem/cilastatin 
(Tienam), meropenem or doripenem in unstable patients; 
D. Fluoroquinolone-based regimens (in cases of stable patients with allergy to beta-
lactams) - ciprofloxacin or levofloxacin in combination with metronidazole, or 
moxifloxacin.  
E. Tigecycline in the stable patient with risk for ESBL. 
In hospital-acquired infections: 
A. Tigecycline + piperacillin/tazobactam (in stable patients);  
B. Imipenem/cilastatin +/- teicoplanin (unstable patients only);  
C. Meropenem +/- teicoplanin (unstable patients only);  
D. Doripenem +/- teicoplanin (unstable patients only) (8). 
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2 BACKGROUND 
 
Gallstone disease together with secondary gallstone-related complications are one of the most 
common reasons for surgery worldwide. In Sweden, around 13,000 patients undergo 
gallbladder surgery each year (48, 49), and in the UK, 70,000 procedures are performed 
annually (50). The procedure is usually performed with no major risk for the patient, though 
there are minor postoperative complications and a general mortality rate < 1% (51). However, 
the high volume of the procedure renders it one of the most important causes of PIC and 
prescription of antibiotics in surgical practice.   
Of all cholecystectomies performed and registered in GallRiks during 2016, 37 % were 
emergency procedures. Cholecystectomy was most often performed for bile colic (71%). The 
second most common cause, however, was acute inflammation (26%) of the gallbladder due 
to gallstone obstruction of the bile duct (34). In NY, the indication for Lap-C is quite the 
opposite, with ACC around 73 % and biliary colic 5 %; the remainder having other 
indications (52). 
In various hospitals in Sweden, the overall postoperative complication rate after planned 
cholecystectomy ranges from 1 % to 11 %. However, the rate is higher after acute 
cholecystectomy; reaching 20 % in some hospitals (34). Although the risk for postoperative 
complications after acute cholecystectomy is higher, including an infectious complication rate 
of 3-17 % (8, 53), the role of AP in Lap-C for AC has not been fully evaluated.  
Antibiotic prophylaxis in elective surgery has been studied in several trials and many meta-
analyses. Results have shown no or only minor benefit regarding PIC (50, 54-57). In a meta-
analysis by Pasquali based on 19 RCTs with a total of 5,259 patients, where perioperative AP 
was defined as antibiotics given preoperatively and/or postoperatively, only a minor benefit 
without significance from AP was seen. The rate of SSI was 2.4% and 3.2% (P=0.21) in the 
antibiotic group and non-antibiotic group, respectively. Nor did the risk for nosocomial 
infection differ significantly between the groups, with rates of 4.2% and 7.2% (P=0.13) in the 
antibiotic and non-antibiotic groups, respectively. The authors concluded that antibiotic 
administration before Lap-C in patients with biliary colic and low to moderate risk 
cholecystitis is not to be recommended (50). Unfortunately, this analysis included studies on 
both elective (n=17) and acute (n=2) procedures. Furthermore, one of the studies on elective 
procedures included patients with history of inflammation. The meta-analysis also included a 
trial where three doses of antibiotics were given to all patients with mild to moderate AC. 
Another meta-analysis (58) showed that AP during elective Lap-C is safe and effective in 
reducing SSI, global infections and hospital stay. This meta-analysis included 21 RCT trials 
covering 5207 procedures, where only two studies showed an OR in favour of prophylactic 
antibiotics; a study from Nepal1999, where 93 % were female and age range between 18-74 
years (59) and one by Matsui including 1037 procedures showing the highest influence on 
outcome (60).  
A study by Matsui and co-workers is so far the only study to show benefit of antibiotic 
treatment in elective Lap-C. It was conducted as a RCT in Japan 2009-2013, with a total 1037 
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participants. Patients in the study were randomised between antibiotic treatment with 3 doses 
of a first-generation cephalosporin, starting at the time of skin incision, and no antibiotics in 
the other arm. They showed a significantly reduced postoperative infectious complication 
rate; SSI 0.8% vs. 3.7%, distant infection; 0.4% vs. 3.1%, and overall infection; 1.2% vs. 
6.7% for antibiotic vs. non-antibiotic groups, respectively. The study did, however, have 
some weaknesses. Allocation was not blinded to the surgeon, and it was unclear whether it 
was blinded to the patients and staff. It was also unclear how soon the procedure was 
scheduled after the latest episode of AC. No information was given about inflammation status 
before or during the operation. The patients were treated with a drain if spill of bile occurred, 
despite the lack of evidence supporting insertion of a sub-hepatic drain after elective surgery 
to prevent intra-abdominal abscess. Routine urinary catheterisation was used, and the patients 
stayed in hospital for approximately 4 days postoperatively, which could indicate that these 
were not low-risk Lap-C procedures. The majority of the postoperative infectious 
complications were SSI and urinary tract infections. Patients were given antibiotics on 
postoperative Days 1 or 2 if they had fever of unknown origin (60). These issues make it hard 
to compare this study with those on elective procedures on low-risk patients as performed in 
the majority of units in the Western world, where most procedures are done as day case 
surgery, with no drain and no urinary catheter. However, the Number Needed to Treat (NNT) 
to prevent SSI in this study was 34, which leads to the conclusion that the use of AP in low-
risk procedures is questionable. This was even more pronounced in another study on the 
benefit of AP in preventing superficial SSI after elective surgery, where the NNT was too 
high (45) for AP to be of worthwhile clinical benefit to the patient (56).  
Nevertheless, 20-80% of patients undergoing cholecystectomy with low to moderate risk for 
SSI receive AP in mixed cohorts of planned and acute cholecystectomies (50, 61). A similar 
pattern is seen in the UK and Ireland, where use of antibiotic prophylaxis in routine elective 
Lap-C still varies between surgeons four years after national guidelines on AP in routine Lap-
C were published. Thirty-six per cent of surgeons (78 % consultants) still give single-dose AP 
before routine Lap-C even if no risk factors are present. Should a perioperative complication 
occur, e.g. bile spillage or presence of gallbladder empyema, then treatment varies greatly 
between surgeons from no treatment at all to one dose, 3 doses, 5 days or > 5 days antibiotics 
(61). Current guidelines diverge in their recommendations on AP. The World Society of 
Emergency Surgery (WSES) does not recommend postoperative AP in uncomplicated 
cholecystitis, but that it should be given in complicated cases (8). The Scottish Intercollegiate 
Guideline Network (SIGN) and the Society of American Gastrointestinal and Endoscopic 
Surgeons (SAGES), on the other hand, recommend that AP be reserved for high-risk patients 
only (61). Other guidelines recommend AP for open surgery and high risk Lap-C but not for 
low risk Lap-C (acute Lap-C not mentioned) (62). The latest Tokyo Guidelines recommend 
AP or no AP during cholecystectomy for Grade I cholecystitis without providing any further 
criteria when AP is indicated (30). 
The procedure and actual inflammation status of the patient are highly predictive of the risk 
for postoperative complication. Patient-related risk factors should be taken into account when 
deciding on AP (51) especially age >65 years, comorbidity and male gender. SIGN (2008) 
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and SAGES (2010) recommend reservation of AP for high-risk patients and procedures only, 
and that AP should be avoided in low-risk patients. They define high-risk patients as: >60 
years old, history of diabetes, acute symptoms of biliary colic within 30 days before surgery, 
jaundice, AC or cholangitis, immunosuppression and pregnant women. High-risk procedures 
are defined as: intraoperative cholangiography, conversion to laparotomy, insertion of 
prosthetic devices and intraoperative bile spillage (61). Spillage of bile, however, is 
encountered in almost 25% of elective Lap-Cs but has not been found to predict PIC. A 
single dose of cephalosporin did not affect occurrence of infection after bile spill either (63). 
Not even Valvular heart disease or valve replacement, which appears to be the comorbidity 
that most surgeons still pay attention to and consider being an indication for AP in 
cholecystectomy, is an unequivocal indication for AP. There is no evidence supporting the 
use of AP in these situations to prevent infective endocarditis according to the National 
Institute for Health and Care Excellence (NICE) guidelines from 2008 (61). 
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3 AIMS OF THE THESIS 
 
Overall aim 
To assess the role of antibiotic prophylaxis in preventing postoperative infectious 
complications after acute cholecystectomy for acute calculous cholecystitis.  
 
 
Specific aims 
 
Paper I 
To explore the impact of antibiotic prophylaxis on postoperative infectious complication after 
acute cholecystectomy in a population-based setting.    
 
Paper II 
To investigate differences in use of antibiotic prophylaxis in cholecystectomy between 
regions, hospitals and surgeons.   
 
Paper III 
To explore the clinical impact of patient- and procedure-related risk factors on the occurrence 
of postoperative infectious complications. 
  
Paper IV 
To determine the effect of preoperative antibiotic prophylaxis, given prior to acute 
cholecystectomy in mild to moderate acute cholecystitis, on the occurrence of postoperative 
infectious complication. 
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4 DATA SOURCES USED IN THE THESIS (I-III) 
 
4.1 SWEDISH REGISTRY FOR GALLSTONE SURGERY AND 
ENDOSCOPIC RETROGRADE 
CHOLANGIOPANCREATOGRAPHY (GALLRIKS) 
GallRiks is a nationwide register that was started in 2005. Six months after its start, 26 units 
were registered in GallRiks, and by the end of 2016, 83 hospitals were affiliated. As with 
other patient registers, the primary purpose of GallRiks is to assure quality of care and patient 
safety, as well as to provide a database for clinical research. It is approved by the Swedish 
National Board of Health and Welfare and the Swedish Surgical Society (that also appoints 
the members of the GallRiks Board).  Since 2009, GallRiks has 85 % coverage of all 
laparoscopic and open cholecystectomies, and all endoscopic interventions of the bile ducts 
performed in Sweden.  
The register uses a web-based form (see appendix for the form). The surgeon or endoscopist 
who performs the procedure registers all relevant data intra- or postoperatively. Each 
affiliated unit has a coordinator who registers postoperative complications, including 
infections, 30 days and 6 months after procedures. In cases where data are missing, the 
coordinator bids the surgeon responsible to complete the form properly. The director of each 
unit affiliated is responsible for ensuring that every cholecystectomy and endoscopic 
retrograde cholangiopancreatography has been registered by the end of the year.  The medical 
records are reviewed by the coordinators to check that all postoperative complications are 
registered. 
Annual validation of data in GallRiks between 2007 and 2011, based on comparison with the 
medical records, showed continual improvement reaching 73% completeness by the end of 
2011. Erroneous data on one or more of the 43 variables validated were found in only 17% of 
registrations at the end of the period (48). The coverage today is 90% and 97% of data match 
the medical records (www.GallRiks.se) based on the annual validation program where 
selected hospitals are visited to check the accuracy of data. 
4.2 NATIONAL PATIENT REGISTER (NPR) 
The National Patient Register (NPR) was started in the 1960’s when the National Board of 
Health and Welfare in Sweden began collecting data on inpatients discharged from public 
hospitals. Since 1987, the NPR has had national coverage, and since 2001 the register has 
also included all hospital outpatient visits. The primary healthcare system is not covered. 
Variables registered in the NPR include patient data, geographical data, administrative data 
and medical data. Under-reporting of inpatient data has been estimated to <1 %. Every 
Swedish citizen has a unique personal identity number, and this makes it possible to track 
patients over time. Data on non-residents, asylum seekers and new-borns, however, may be 
missing. All inpatient diagnoses are registered according to the International Classification of 
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Diseases (ICD) codes (64). The surgeon responsible for the discharge of a patient after 
surgery registers all diagnosis codes. NPR is regularly validated, showing that 99% of all 
discharges are registered with all relevant diagnoses coded according to the ICD. Degree of 
correctness ranges from 85 to 95% (65).
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5 PAPER I 
 
This was a study on a population-based cohort of all acute cholecystectomies performed in 
Sweden between January 2006 and December 2010. Data were retrieved from GallRiks. The 
inclusion criteria were: patients undergoing acute cholecystectomy before discharge after 
emergent admission; indication for the surgery being gallstone-related disease or acalculous 
cholecystitis; and surgery performed at a unit where at least 50 procedures had been 
performed during the study period. A total of 13911 patients were included. Confounding 
variables extracted from GallRiks were: age; gender; indication for surgery; ASA class; 
surgical approach; duration of surgery; accidental gallbladder perforation; and AP. AP was 
defined as antibiotic treatment lasting up to one day, or antibiotic treatment lasting more than 
one day given in repeated doses before, during and after the procedure. PIC within 30 days 
after surgery, as registered by the local coordinator at each hospital, were also retrieved from 
GallRiks to define the two outcomes measures: 
PIC included conditions requiring antibiotic treatment, i.e. PIC related to the procedure or 
nosocomial infection.Intra-abdominal abscess included abscesses diagnosed in the 
postoperative period using imaging diagnostics, regardless of whether requiring percutaneous 
drainage or not. 
Statistical analyses 
χ2 test was used to analyse associations between clinical and surgical variables and use of 
AP. Univariate and multivariate logistic regression analyses were performed, where AP was 
treated as a variable together with other covariables (age, gender, indication for surgery, ASA 
class, surgical approach, duration of surgery, and accidental gallbladder perforation) in a 
stepwise inclusion model. Subgroup analyses were performed for patients with perioperative 
AC, jaundice and accidental gallbladder perforation. Odds ratio was presented with 95% 
confidence interval, where (p<0.05) was considered statistically significant. R version 2.15.3 
was used for statistical analyses.  
Results  
Altogether, 13,911 procedures were included in the study. AP was given to 68.6 % whereas 
31.4 % did not get antibiotics. The subgroup of patients with AC included 8,205 procedures, 
the subgroup with obstructive jaundice included 2,786 procedures, and the group of 
accidental gallbladder perforation included 3,938 patients.  The subgroup of patients with 
obstructive jaundice group also included those with other complications related to common 
bile duct stones such as pancreatitis and cholangitis. 
Baseline data are presented in Table 2. Age was distributed as follows: <40 years (30.4%); 
41-60 years (34.3%); and >60 years (35.3%).  There were 39.3 % men and 60.7 % women. 
Indication for surgery was either complicated, i.e. cholecystitis, pancreatitis or obstructive 
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jaundice or acalculous cholecystitis (73.2%), or uncomplicated, i.e. biliary colic (26.8%).  
Altogether 51.2% were ASA class 1 (and 48.8% were class 2 or more Surgical approach was 
either open (i.e. open cholecystectomy, laparoscopic converted to open cholecystectomy, 
subtotal cholecystectomy and mini-laparotomy (46.6%), or laparoscopic cholecystectomy 
(53.4%).  Duration of surgery was <90 minutes in (39.2%) or >90 minutes in (60.8%) of the 
cases. Gallbladder perforation occurred in 28.6%. The total PIC rate was 7.6 %, including 1.5 
% abdominal abscesses and 6.1 % PIC. Comparing the group of patients who received AP 
with those who did not, the adjusted OR was 0.93 (95% confidence interval [CI] 0.79-1.10) 
for PIC and 0.88 for intra-abdominal abscess (95% confidence interval [CI] 0.64-1.21). 
 
Variable 
 
All patients  
(n = 13,911) 
 
No antibiotic 
prophylaxis 
(n = 4,362) 
Antibiotic 
prophylaxis  
(n = 9,549) 
P† 
Age (years)    < 0.001    
      ≤ 40 4,216 (30.3) 2,055 (47.3) 2,161 (22.7) 
      41–60 4,754 (34.2) 1,478 (34.0) 3,276 (34.4)   
      > 60 4,890 (35.2) 808 (18.6) 4,082 (42.9)   
      Unknown 51 (0.4) 21 30  
Gender (M: F) 5,468: 8,443 1,217: 3145 4,251: 5,298 < 0.001    
Indication for cholecystectomy    < 0.001    
       Uncomplicated 3,732 (26.8) 2,063 (47.3) 1,669 (17.5) 
 
      Complicated* 10,179 (73.2) 2,299 (52.7) 7,880 (82.5)   
ASA class    < 0.001    
      I 7,125 (51.2) 2,791 (64.0) 4,334 (45.4)  
      > I 6,786 (48.8) 1,571 (36.0) 5,215 (54.6)   
Surgical approach    < 0.001    
      Open 5,175(37.2) 7,15(16.4) 4,460 (46.7)  
      Laparoscopic 8,736(62.8) 3,647 (83.6) 5,089(53.3)   
Duration of surgery (min)    < 0.001    
      < 90 5,456 (39.2) 2,451 (56.2) 3,005 (31.5)  
      ≥ 90 8,450 (60.7) 1,909 (43.8) 6,541 (68.5)   
      Unknown 5 (< 0.1) 2 3  
Gallbladder perforation    < 0.001    
      No 9,827 (70.6) 3,415 (79.0) 6,412 (67.9)  
      Yes 3,938 (28.3) 909 (21.0) 3,029 (32.1)   
      Unknown 146 (1.0) 38 108  
Postop. infection requiring 
antibiotics 
   < 0.001    
      No 12,837 (92.3) 4,095 (93.9) 8,742 (91.6)  
      Yes 1,070 (7.7) 265 (6.1) 805 (8.4)   
      Unknown 4 (< 0.1) 2 2  
Abscess    0.007   
      No 13,638 (98.0) 42,97 (98.5) 9,341 (97.8)  
      Yes 273 (2.0) 65 (1.5) 208 (2.2)   
Values in parentheses are percentages. *Pancreatitis, obstructive jaundice, cholecystitis and acalculos 
cholecystitis. † χ2 test used  
Table 2: Baseline data. 
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In the subgroup of patients with AC (n=8,205), 96.3 % had ACC and 3.7% acalculous 
cholecystitis. The total PIC rate in this group was 10.7%, with PIC 8.5% and abdominal 
abscess 2.2%. Comparing the group who received AP with those who did not, the adjusted 
OR was 0.84 (95% confidence interval [CI] 0.67-1.06) for PIC and 0.72 for intra-abdominal 
abscess (95% confidence interval [CI] 0.47-1.1).  
In the subgroup of patients with obstructive jaundice (n= 2,786), the total PIC rate was 11 %, 
with PIC 9.1 % and intra-abdominal abscess 1.9 %. Comparing the group who received AP 
with those who did not, the adjusted OR was 0.75 (CI 0.54-1.05) for PIC and 0.69 (CI 0.34-
1.4) for intra-abdominal abscess.  
In the subgroup of patients with accidental gallbladder perforation, regardless of indication 
for surgery (n=3938), the total PIC rate was, 9.7 %, rate of complications requiring antibiotics 
7.7% and intra-abdominal abscess 2.0%. When comparing the group of patients who received 
AP with those who did not, the adjusted OR was 1.09 (95% confidence interval [CI] 0.78-
1.5) for PIC and 0.93 (95% confidence interval [CI] 0.50-1.71) for intra-abdominal abscess.  
Univariate and multivariate logistic regression ORs regarding outcomes, for patients in the 
whole group as well as for those in the subgroups, are presented in Table 3. 
The multivariate analysis of impact of AP (Figs 5 and 6) on outcomes were added stepwise to 
the univariate OR, starting with gender in Model 1, gender + age in Model 2, and thereafter 
adding indication for cholecystectomy, ASA class, surgical approach, duration of surgery, 
and finally accidental gallbladder perforation in Model 7. The OR decreased for each 
covariate added, but never reached the level of statistical significance. The final OR was 0.93 
(CI 0.79-1.10) for PIC and 0.88 (CI 0.64-1.21) for intra-abdominal abscess. 
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 Analysis† n Odds ratio  
All patients     
Postop. infection requiring antibiotics Univariate  13,907 1.42 (1.23, 1.64) 
Adjusted 13,707 0.93 (0.79, 1.10) 
Abscess Univariate 13,911 1.47 (1.11, 1.95) 
 Adjusted 13,711 0.88 (0.64, 1.21) 
Cholecystitis subgroup     
Postop. infection requiring antibiotics Univariate 8,203 1.25 (1.01, 1.55) 
Adjusted 8,090 0.84 (0.67, 1.06) 
Abscess Univariate 8,205 1.13 (0.76, 1,69) 
 Adjusted 8,092 0.72 (0.47, 1.11) 
Obstructive jaundice subgroup*     
Postop. infection requiring antibiotics Univariate 2,785 1.19 (0.88, 1.62) 
Adjusted 2,735 0.75 (0.54, 1.05) 
Abscess Univariate 2,786 1.17 (0.61, 2.24) 
 Adjusted 2,736 0.69 (0.34, 1.4) 
Gallbladder perforation subgroup     
Postop. infection requiring antibiotics  Univariate 3,937 1.43 (1.05, 1.94) 
Adjusted 3,923 1.09 (0.78,1.52) 
Abscess Univariate 3,938 1.19 (0.68, 2.06) 
 Adjusted 3,924 0.93 (0.50, 1.71) 
Values in parentheses are 95 per cent confidence intervals. *Surgery with jaundice as indication and/or common 
bile duct stone diagnosed at peroperative cholangiography.  †Results are shown for the final adjusted model 
(Model 7). An odds ratio of less than 1 favours antibiotic prophylaxis. 
Table 3: Logistic regression analyses of patients undergoing cholecystectomy for acute 
gallstone disease.
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Figure 5: Multivariate analyses of impact of antibiotic prophylaxis on development of 
postoperative infectious complication necessitating antibiotic treatment. OR with 95 % 
confidence intervals. OR less than 1 favours antibiotic prophylaxis. 
 
Figure 6: Multivariate analyses of impact of antibiotic prophylaxis on development of 
abscess. OR with 95 % confidence intervals. OR less than 1 favours antibiotic prophylaxis. 
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6 PAPER II 
 
All cholecystectomies registered in GallRiks between 2005 and 2015 (n=113,209) constituted 
the base for this cohort study. Covariate variables retrieved from GallRiks were: age (≤40 
years, 41-60 years  and ≥60 years); gender; ASA class (1 or ≥2); indication for surgery 
(uncomplicated versus complicated); approach (laparoscopic including laparoscopic 
cholecystectomy, mini-incision cholecystectomy and open for other approaches);  duration of 
the procedure (<90 minutes or ≥90 minutes); accidental gallbladder perforation; urgency 
status (acute or planned); year of surgery; and AP (including both treatment lasting ≤24 hours 
and that continued >24 hours).  
The exclusion criteria were: Hospitals and surgeons with less than 25 cholecystectomies 
registered during the study period; patients with data missing on any of the variables; data 
missing on the surgeon responsible; exploration of the common bile duct without 
concomitant cholecystectomy; indication for surgery other than gallstone-related; emergency 
procedure on patients with impaired vital function; duration of the procedure unknown or 
registered as >24 hours (assumed to be erroneous).  
The numbers of patients excluded are presented in Table 4. There were no data on type of 
antibiotic given in GallRiks, only the duration. 
 
Criterion                                                                           Number remaining patients 
Original data 
Antibiotics treatment known 
Surgeon known 
ASA class known 
Removed: indication “undergoing other surgery” 
Removed: operation method “undergoing common bile duct exploration” 
Duration of surgery ≤24 hours known 
Age known 
Gender known 
Gallbladder perforation known 
Urgency status known 
Removed: institution with fewer than 25 patients 
113,209 
110,301 
109,681 
109664 
109,196 
109,108 
109,083 
108,841 
108,839 
108,502 
107,925 
99,101 
Table 4: Assembly of the study cohort. 
 
The study was approved by the Stockholm Ethics Review Committee. All participants gave 
informed consent to inclusion. The study was conducted in accordance with the Helsinki 
Declaration.   
The outcome was use of AP at different healthcare levels; region, hospital and surgeon.  
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Statistical analyses 
The R version 2.14.1 (2011-12-22) and WinBugs 1.4 were used for the statistical analyses.  
Funnel plots were applied to create a graphical presentation of the region’s, hospital’s and 
surgeon’s use of antibiotics outside the confidence intervals. Regions, hospitals or surgeons 
deviating from the general population by more than could be expected, i.e. outside 95% CI; if 
there had been an underlying uniform approach and random variation at each level (66).  The 
funnel plots were used to study grouping factors, i.e. region, hospital and surgeon. In plain 
funnel plots, each indicator is equal to the proportion of the patients that received antibiotics 
(y axis), and on the x is the total number treated at the units (region, hospital and surgeon) 
(Figs 7-9). The 95% confidence intervals were defined as θ0 ± 1.96 x  , where 
 is the proportion of patients receiving antibiotics in the whole population and n is the 
number of patients undergoing surgery in the region, hospital, or by the surgeon.  
In the regression funnel plots, the indicators were derived from a regression model after 
adjusting for covariates (age, gender, ASA class, indication for surgery, approach, duration of 
the procedure, accidental gallbladder perforation, and urgency status) using Bayesian 
multilevel regression model (Figs 10-12). The regression funnel plots enabled identification 
of specific differences at a certain level (e.g. region) beyond those that could be explained by 
differences at other levels (hospital/surgeon). This implies that if a hospital deviates from the 
total population, it remains within the confidence intervals in the multilevel regression funnel 
plots if it does not deviate extremely from the other units in the same region. In other words, 
the hospital’s variation and value outside the 95% confidence interval in the regression funnel 
plot, cannot be explain by a routine at the region level. The statistical basis of this study had 
been described in detail previously (66).  
Funnel plots are used to illustrate credibility intervals, i.e. the Bayesian analogy to confidence 
intervals. The main difference is the use of fixed boundaries and estimated parameters as the 
random variable, and not vice versa. 
Indicators outside the 99.9% confidence interval were considered highly clinically relevant.  
Results  
A total of 113,209 patients were included in the study. Patients excluded (14,108) are 
presented in Table 4. A complete case-analysis was performed for the study group of 99,101 
subjects. The baseline data for each covariate are given in Table 5. The number of patients 
2005-2006 was relatively small (6,477), these two years were therefore pooled together in 
order to gain more balanced categories. The covariate effect on the choice of AP in a fixed 
effect is shown in Table 6.  All covariates were associated with the decision to give AP, and 
this increased slightly for each year. The factor having the greatest impact was open surgical 
approach, with an OR of 4.87 (CI 4.56-5.16).  
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The funnel plots for AP proportions, without adjustment for confounders or level (region, 
hospital and surgeon) are shown in Figs 7-9. There were 15/21 (71%) outside the 99.9% 
confidence interval at region level, 61/76 (80%) at the hospital level and 400/1038 (39%) at 
the surgeon level. Large deviations were observed at each level.  
 
Figure 7. Plain funnel plot for regions. Outliers: 15/21 (71%) 
 
Figure 8. Plain funnel plot for hospitals. Outliers: 61/76 (80%) 
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Figure 9. Plain funnel plot for Surgeons. Outliers: 400/1038 (39%)  
The regression funnel plots with adjustment for confounding covariates and levels are shown 
in Figs 10-12. There was no deviation outside the 95% confidence interval at the region level, 
but there were 18/76 (24%) and 128/1038 (128) indicators outside the 99.9% confidence 
interval at hospital and surgeon levels, respectively.  
 
Figure 10. Covariate−adjusted multilevel funnel plot for regions. Outliers: 0/21 (0%) 
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Figure 11. Covariate−adjusted multilevel funnel plot for hospitals. Outliers: 18/76 
(24%) 
 
Figure 12. Covariate−adjusted multilevel funnel plot for surgeons. Outliers: 128/1038 (12%) 
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Variable No antibiotic 
N =66995 
Antibiotic given 
N=32106 
Combined 
N=99,101 
Age:  
   ≤40 
   41-60 
   >60 
Gender:  
   Male 
   Female 
ASA class: 
   1 
   >1 
Indication: 
   Uncomplicated 
   Complicated 
Surgical technique: 
   Laparoscopic 
   Open 
Duration of surgery (min): 
   <90  
   ≥90 
Gallbladder perforation: 
   No 
   Yes 
Urgency: 
   Elective 
   Emergency 
Year: 
  2005-2006 
  2007-2015 
 
23,114 (77.5%) 
27,621 (70.3%) 
16,260 (54.2%) 
 
18,775 (57.1%) 
48,220 (72.8%) 
 
38,134 (74.8%) 
28,861 (60.0%) 
 
49,722 (84.2%) 
17,273 (43.1%) 
 
63,791 (73.9%) 
3,204 (25.1%) 
 
41,010 (81.4%) 
25,985 (53.4%) 
 
50,878 (73.5%) 
16,117 (53.9%) 
 
56,475 (82.4%) 
10,520 (34.5%) 
 
3,938 (60.8%) 
63,057 (68.1%) 
 
6,720 (22.5%) 
11,671 (29.7%) 
13,715 (45.8%) 
 
14,081 (42.9%) 
18,025(27.2%) 
 
12,854 (25.2%) 
19,252 (40.0%) 
 
9,331 (15.8%) 
22,775 (56.9%) 
 
22,534 (26.1%) 
9,572 (74.9%) 
 
9,386 (18.6%) 
22,720 (46.6%) 
 
18,329 (26.5%) 
13,777(46.1%) 
 
12,093 (17.6%) 
20,013 (65.5%) 
 
2,539 (39.2%) 
29,567(31.9) 
 
29,834 
39,292 
29,975 
 
32,856 
66,245 
 
50,988 
48,113 
 
59,053 
40,048 
 
86,325 
12,776 
 
50,396 
48,705 
 
69,207 
29,894 
 
68,568 
30,533 
 
6,477 
92,624 
Table 5: Baseline data of the study group. 
 
Variable Reference Level Odds ratio 95% CI 
Age (years) ≤ 40 41-60 1.43 (1.36, 1.50) 
  >60 1.93 (1.83, 2.04) 
Gender Male Female 0.79 (0.76, 0.82) 
Year 2005/2006 2007 1.22 (1.13, 1.32) 
  2008 1.17 (1.08, 1.25) 
  2009 1.04 (0.97, 1.11) 
  2010 0.93 (0.87, 0.99) 
ASA class 1 ≥2 1.29 (1.24, 1.35) 
Surgical approach Laparoscopic Open 4.87 (4.56, 5.16) 
Duration of surgery (min) <90 ≥90 2.65 (2.53, 2.76) 
Indication Uncomplicated Complicated 2.70 (2.59, 2.82) 
Gallbladder perforation No Yes 2.48 (2.37, 2.58) 
Table 6: Estimates and credibility intervals for the fixed effects.
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7 PAPER III 
 
The study population for this cohort was obtained from GallRiks and NPR.  
Data on all cholecystectomies registered in GallRiks between 2006 and 2014 were retrieved. 
The procedure and relevant patient-related risk factors obtained from GallRiks were: age 
(<70 or ≥70 years old); gender; ASA class (1 or ≥2); indication for surgery (uncomplicated 
(bile colic) or complicated (gallstone-related complications); surgical approach (laparoscopic 
or open, including conversion from laparoscopic to open surgery and mini-laparotomy); 
duration of surgery (<120 minutes or ≥120 minutes); antibiotic treatment (including 
continuous treatment and single-dose prophylaxis); and accidental gallbladder perforation. 
The covariant variables obtained from IPR were: history of connective tissue disease (ICD 
codes M05-06, M 31.5, M32-M34, M35.1, M35.3 and M36.6); diabetes mellitus (ICD codes 
E10-E14); chronic kidney disease (ICD codes N03.2-N03.7, N05.2-N05.7, N18, N19, I12.0, 
I13.1, Z49.0-Z49.2, Z94.0, Z99.2); liver cirrhosis (ICD codes K70.3, K71.7, K74, I85); 
immunodeficiency (ICD codes D80-D89); and obesity (ICD code E86). Only diagnoses 
registered before the date of surgery were used.  
In the present study, a PIC was defined as a complication registered in GallRiks and/or NPR. 
PIC were registered in GallRiks 30 days after the procedure, based on patient records, and 
relevant patient diagnoses were obtained from the NPR, including outcome diagnoses (ICD 
codes T81.4 = infection after surgical or medical procedure, K 83.0 = cholangitis, and A40 
and A41= septicaemia).  
A cross-checking between NPR and GallRiks was performed for outcome and comorbidity 
diagnoses.  
Outcomes were surgical site infection SSI including PIC necessitating antibiotic treatment or 
percutaneous drainage and septicaemia, including diagnoses of cholangitis and or 
septicaemia.  
The study was approved by the Regional Research Ethics Committee in Stockholm, Sweden. 
All data were imported retrospectively and processed without entering patient records.  
Statistical analysis 
Univariate and multivariate logistic regression analyses were used to analyse patients and 
procedure-related risk factors for SSI and septicaemia.  Odds ratio (OR) with 95% confidence 
interval was conducted and a p value <0.05 was considered significant.  
Results  
In total, 94,557 cholecystectomy procedures registered in GallRiks between 2006 and 2014 
were included.  
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SSI or infection requiring antibiotics was registered in 4,835 (5.2%) of the procedures in 
GallRiks. Wound infections within 30 days postoperatively were registered after 1,532 
(1.6%) of the procedures. Any infection, i.e. wound infection and/or septicaemia, were 
registered in the NPR after 2016 of the procedures. SSI or infection requiring antibiotics was 
registered in both GallRiks and the NPR in 1,136 of the procedures.  
There were only 63 procedures in which sepsis and/or septic cholangitis within 30 days 
postoperatively was registered in GallRiks as well as in the NPR. Septicaemia was registered 
in the NPR following 538 procedures (0.6%). Postoperative septic cholangitis was registered 
following 175 procedures (0.2%) in GallRiks.  
The outcome of the simple logistic regression analysis is presented in Table 7. OR for the 
outcome SSI was statistically significant, with 95% confidence intervals for all confounders 
and comorbidities except immunodeficiency. The OR for septicaemia was statistically 
significant for all variables except accidental gallbladder perforation, immunodeficiency and 
obesity (Table 7).  
The multivariate logistic regression analyses were performed with adjustment for the 
confounders retrieved from GallRiks (age, gender, ASA class, indication for surgery, surgical 
approach, duration of surgery, antibiotic treatment and accidental gallbladder perforations, 
Table 8). For the outcome SSI, the adjusted OR was significantly higher for connective tissue 
disease (OR 1.40, CI 1.21-1.63), complicated (OR 1.44, CI 1.21-1.71) and uncomplicated 
diabetes (OR 1.39, CI 1.26-1.53), chronic kidney disease (OR1.79, CI 1.46-2.19), cirrhosis 
(OR 1.76, CI 1.27-2.45) and obesity (OR 1.63, CI 1.48-1.80) but not for immunodeficiency 
(OR 0.86, CI 0.58-1.28). The adjusted OR for the second outcome, septicaemia was 
statistically significant for chronic kidney disease (OR 5.02, CI 3.02-8.34) and cirrhosis (OR 
3.07, CI 2.12-4.43) only.  
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Variable Surgical site infection Septicaemia 
 Simple logistic regression analyses for SSI Simple logistic regression analyses for septicaemia 
 N % p-value Odds 
Ratio 
CI N % p-value Odds 
Ratio 
CI 
Age,>70 years vs <70 
years 
1,375/12,725 10.8 <0.001 2.41 2.25-2.57 232/12,725 1.8 <0.001 3.52 3.00-4.14 
Gender, male vs female 2,255/31,068 7.3 <0.001 1.55 1.47-1.64 341/31,068 1.1 <0.001 2.19 1.88-2.55 
ASA >1 vs 1 3,493/45,385 7.7 <0.001 2.19 2.06-2.32 501/45,385 1.1 <0.001 3.42 2.86-4.09 
Indication for surgery, 
gallstone pain or 
complication of gallstone 
disease  
3,216/39,876 8.1 <0.001 2.21 2.09-2.34 514/39,876 1.3 <0.001 4.84 4.03-5.82 
Open approach, including 
conversion from 
laparoscopic to open or 
laparoscopic 
1,868/13,450 13.9 <0.001 3.71 3.49-3.93 309/13,450 2.3 <0.001 5.71 4.88-6.67 
Op. time >120 min 1,985/22,711 8.7 <0.001 1.99 1.88-2.11 301/22,711 1.3 <0.001 2.76 2.36-3.22 
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Antibiotic treatment 2,632/31,025 8.5 <0.001 2.13 2.02-2.25 438/31,025 1.4 <0.001 4.32 3.66-5.10 
Accidental gallbladder 
perforation  
1,868/27,490 6.8 <0.001 1.36 1.29-1.45 201/27,490 0.7 0.226 1.11 0.94-1.31 
Connective tissue disease 216/2,035 10.6 <0.001 2.04 1.77-2.36 38/2,035 1.9 <0.001 2.81 2.02-3.91 
Complicated diabetes  166/1,269 13.1 <0.001 2.59 2.19-3.05 27/1,269 2.1 <0.001 3.18 2.15-4.69 
Uncomplicated diabetes  608/ 5,283 11.5 <0.001 2.35 2.15-2.57 97/ 5,283 1.8 <0.001 2.94 2.37-3.66 
Chronic kidney disease  123/788 15.6 <0.001 3.17 2.61-3.85 33/ 788 4.2 <0.001 6.48 4.54-9.27 
Cirrhosis  44/ 345 12.8 <0.001 2.48 1.80-3.40 17/ 345 4.9 <0.001 7.53 4.60-12.34 
Immunodeficiency 28/ 489 5.7 0.904 1.02 0.70-1.50 4/ 489 0.8 0.752 1.17 0.44-3.15 
Obesity 507/ 6,173 8.2 <0.001 1.56 1.42-1.72 46/ 6,173 0.7 0.653 1.07 0.79-1.45 
Table 7: Univariate logistic regression analyses for SSI and septicaemia with covariates indicated. 
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Conditions Multivariate logistic analyses for 
SSI 
Multivariate logistic analyses for 
septicaemia 
 p-value Odds 
Ratio 
CI p-value Odds 
Ratio 
CI 
Connective tissue 
disease 
<0.001 1.40 1.21-1.63 0.004 1.66 1.17-2.34 
Complicated 
diabetes  
<0.001 1.44 1.20-1.71 0.158 1.35 0.89-2.03 
Uncomplicated 
diabetes  
<0.001 1.39 1.26-1.53 0.023 1.31 1.04-1.66 
Chronic kidney 
disease 
<0.001 1.79 1.46-2.19 <0.001 3.07 2.12-4.43 
Cirrhosis 0.001 1.76 1.27-2.45 <0.001 5.02 3.02-8.34 
Immunodeficiency 0.468 0.86 0.58-1.28 0.916 1.06 0.39-2.85 
Obesity <0.001 1.63 1.48-1.80 0.261 1.20 0.88-1.64 
Table 8: Multivariate logistic regression analysis for patient-related risk factors after 
adjustment for other confounders.  
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8 PAPER IV 
 
The study was designed as single-centre double-blinded randomised controlled prospective 
study. Patients diagnosed with ACC (Grades I and II according to TG18) at Karolinska 
Hospital between January 2009 and May 2017 participated in the study if they fulfilled the 
eligibility criteria. The patients were randomised to 4 g of piperacillin/ tazobactam PAP three 
times daily until surgery, or equivalent volumes of saline.  
Eligibility criteria were: age > 18 years; clinical, biochemical and radiological signs of ACC; 
symptom duration <5 days; and intention to perform cholecystectomy before discharge. 
Exclusion criteria were: signs of organ failure; ongoing sepsis; pregnancy; common bile duct 
obstruction; had taken antibiotics in the last 24 hours; contraindication to surgery; and allergy 
to piperacillin/ tazobactam.  
Written consent was obtained from all participants after receiving verbal and written 
information about the study from a physician at the emergency care unit. Randomisation 
between the two parallel arms was made and the result kept in a sealed envelope. The nurses 
at the emergency care unit, clinicians, surgeons, researchers and the patients were all blinded 
to the allocation. The drip set was covered by an opaque bag to maintain blinding, and the 
infusion was administered by a research nurse. From the day of inclusion, vital parameters 
and blood samples, including CRP and WBC, were documented daily until two days after 
surgery or discharge from the hospital, in order to monitor the inflammatory status of the 
patient. The infusion was repeated 3 times a day if necessary because of delay to surgery due 
to OR availability (79% received one dose only prior to surgery). 
Using a long needle, bile was aspirated from the gallbladder fundus at the start of the 
procedure, and, whenever possible, via the cystic duct prior to cholangiography, and sent for 
culture. In cases where the surgeon performing the procedure found it necessary to interrupt 
blinding and give intraoperative antibiotics or continue antibiotic treatment postoperatively, 
patients remained in the same allocation group for an intention-to-treat analysis.  
The patients were followed up 30 days after the procedure by abstracting data from the 
medical records and interviewing the patient at a follow-up visit or by telephone. 
The outcomes were: PIC requiring antibiotic treatment within 30 days postoperatively (PIC 
defined as SSI, intra-abdominal abscess, sepsis, cholangitis or nosocomial infection such as 
urinary tract infection and pneumonia); postoperative signs of infection without primary 
focus (signs of gallbladder infection, i.e. empyema or necrotic gallbladder, seen 
perioperatively were also included in this endpoint). 
Secondary outcomes were bactibilia and infection marker response (raised CRP, WBC or 
body temperature). 
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This study was approved by the Local Ethics Review Board in Stockholm (2008/1135-31). 
The study is registered at clinicaltrials.gov (NCT02619149).  
Statistical analyses 
The hypothesis was that placebo was not inferior to PAP in preventing postoperative 
infection after acute cholecystectomy.  
The correlation between positive bile culture and rise in infection markers indicating PIC was 
also analysed. 
Variation between groups regarding known risk factors (age, gender, duration of symptoms, 
comorbidity, method of approach) and their effect on PIC was analysed.  
A per-protocol analysis was made, i.e. excluding patients where blinding was interrupted 
during the operation, and patients where no follow-up interview was made.  
A sample size of 77 patients was needed to have a power of 80% to reduce the rate of PIC 
from 25% to 10% in order to detect a clinically and statistically significant difference at the 
p<0.05 level (one-sided test). 
Chi-square and T-test were used to determine differences between the groups regarding 
categorical variables, and Mann Whitney U-test was used to analyse parametric data.  
Results 
The total number of patients included in the study was 106. A flow chart of the study group is 
presented in Fig 13. After the initial drop-out, 90 patients were randomly allocated to one of 
two groups; 42 patients were randomised to the antibiotic group and 48 to the placebo group. 
These groups constituted the intention-to-treat cohort. The surgeon decided to interrupt 
blinding for five patients in the antibiotic group and 10 patients in the placebo group.  The 10 
patients in the placebo group that did not follow the protocol received antibiotic treatment 
intraoperatively and this was continued postoperatively due to severe wound contamination. 
The 5 patients in the antibiotic group that did not follow the protocol continued antibiotic 
treatment postoperatively for the same reason. There were 8 and 9 patients lost to follow-up 
in the antibiotic and placebo groups, respectively. The remaining 78 patients (29 in each 
group) formed the per-protocol group.  
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Figure 13: Flow diagram.  
There was no variation in known risk factors between the two groups (Table 9). The PIC rate 
was lower in the antibiotic group than the placebo group (19% versus 29%), but there was no 
statistically significant difference (p= 0.193). In the per-protocol analyses the PIC rate was 
10% in each group.  
Assessed for eligibility 
(n=106) 
 Excluded (n=16) 
 Not meeting inclusion criteria (n=3) 
 Declined participation (n=1) 
 Overloaded operation program (n=8) 
 Allocation envelope missed (n=4) 
 
 
 
 
Analysed (n=29)  
 
Patients Followed the protocol (n=38) 
Lost to follow-up after protocol (n=9) 
Allocated to placebo (n=48) 
 Received allocated intervention (n=48) 
 Given peroperative antibiotic treatment 
(n=10)  
 
Analysed (n=29) 
 
 
Allocation 
 
Analysis 
 
Follow-Up 
 
Randomized (n=90) 
Enrollment 
Allocated to AP (n= 42) 
 Received allocated intervention (n=42) 
 Despite allocation continued with 
antibiotic treatment (n=5)  
Patients followed the protocol (n=37) 
Lost to follow-up after protocol (n= 8) 
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Variables Intention-to-treat analysis n 90 Per-protocol Analysis (allocation and follow-up) n 58 
 Antibiotic (%) 
42 (47) 
Placebo (%) 
 48 (53) 
p-value Antibiotic  
29 (50) 
Placebo 
29 (50) 
p-value 
Gender, Men (%) 
              Women 
18 (43) 
24 (57) 
23 (48) 
25 (52) 
0.675 13 (45) 
16 (55) 
11 (38) 
18 (62) 
0.395 
Age (IQR) 48.5 (24) 49 (25) 0.768 55 (20) 45 (20) 0.194 
BMI (median) (IQR) 27 (7) 28 (6) 0.874 28 (9) 27 (5) 0.428 
Previous gallstone symptom (%) 13 (31) 11 (30) 0.476 10 (34) 6 (21) 0.379 
No Comorbidity (%) 13 (31) 21 (44) 0,277 8 (28) 14 (48) 0.175 
Symptom duration (median) (IQR) 4 (3) 4 (2) 0.653 4 (3) 4 (1) 0.178 
Op-method (%)   0.487   0.838 
    Laparoscopic 37 (88) 38 (79)  26 (90) 25 (86)  
    Open 1 (2) 3 (6)  1 (3) 2 (7)  
    Converted 4 (10) 7 (15)  2 (7) 2 (7)  
Temp inclusion day (IQR) 37 (21) 37 (1) 0.810 37 (2) 37 (2) 0.433 
CRP inclusion day median (IQR) 57 (121) 81 (129) 0.140 46 (129) 76 (79) 0.409 
LPK inclusion day (median)(IQR) 10 (5) 12 (7) 0.105 9 (6) 10.5 (8) 0.600 
Temp day 2 (median) (IQR) 37 (2) 37(0.5) 0.398 37 (2) 37 (1) 0.893 
CRP day 2 (median) (IQR) 760 (175) 80 (118) 0.650 56 (151) 70 (52) 0.844 
LPK day 2 (median) (IQR) 10 (7) 11 (5) 0.536 8 (8) 10 (4) 0.545 
Antibiotic treatment start postop (%) 5 (12) 10 (21) 0.396 -- --  
Postop complication (%) 8 (19) 14 (29) 0.193 3 (10) 3(10) 0.665 
Table 9: characteristics of study population. 
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The conversion rate was the only variable that differed in patients with PIC, with a higher 
conversion rate from Lap-C to open in the group with PIC (27% compared to 7 % in the non-
event group). The comorbidity rate was also high in the PIC group (77 % versus 57% in the 
non-event group), but the difference was not statistically significant (Table 10). CRP levels 
were significantly higher on the day of allocation and the day following in patients with PIC.  
The total number procedures where bile was sent for culture was 48. In some of the cultures 
more than one bacterial species was found. Altogether 18 cultures were positive and 30 
negative. The predominant agent was gram-negative bacteria (n=11), followed by gram-
positive (n=10). The number of PICs in the antibiotic group (6) was almost significantly 
higher, than in placebo group (3) (p= 0.054). In the group with a positive culture, 67% (n=12) 
did not develop PIC (Table 11). 
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Table 10: Postoperative infectious complications.  
 
 Culture (n=48)   
 Positive (n=18, 37.5%) Negative (n=30,62.5%) P-Value (1s) 
Randomised    0.076 
   Antibiotic 13 (72) 14 (47)  
   Placebo 5 (28) 16 (53)  
Postoperative infectious complications   0.054 
   Non-event 12 (67) 27 (90)  
   Event 6 (33) 3 (10)  
Table 11: Bile culture results. 
Variables Intension-to-treat analysis (90) Per-Protocol analysis (58) 
 Non-event (%) 68 (76) Event (%) 22 (24) p-value Non-event (%) 52 (90) Event (%) 6 (10) p-value 
Men (%) 32 (47) 9 (41) 0.633 22 (42) 2 (33) 1.000 
Age (IQR) 47,5 (24) 58 (25) 0.081 49 (22) 59 (26) 0.301 
BMI (IQR) 27.4 (6.5) 27.7 (6.3) 0.936 28 (7) 28 (6) 0.861 
Symptom duration (IQR) 4 (2) 4 (3) 0.400 4 (2) 5 (4) 0.388 
No Comorbidity (%) 29 (43) 5 (23) 0.075 (1s) 21(40) 1(17) 0.253 (1s) 
Operation method (%)   0.017*   0.335 
    laparoscopic 61 (90) 14 (64)  46 (88) 5 (83)  
    open 2 (3) 2 (9)  2 (4) 1 (17)  
    converted 5 (7) 6 (27)  4 (8)  0 (0)  
Temp allocation day (IQR) 37 (2) 37 (1) 0.513 37(1) 37(1) 0.409 
CRP allocation day (IQR) 57 (121) 124 (118) 0.008* 57(94) 131 (123) 0.102 
LPK allocation day (IQR) 10 (7) 12 (5) 0.258 9 (8) 11 (3) 0.564 
Temp day 1 (IQR) 37 (2) 37 (1) 0.560 37(2) 36 (2) 0.278 
CRP day 1 (IQR) 64 (87) 206.5 (164) 0.004* 58 (63) 113(152) 0.163 
LPK day 1 (IQR) 8.5 (5) 11 (5) 0.053 8 (5) 10 (5) 0.096 
Nr allocated to AP (%) 34 (50) 8 (36) 0.193 (1s) 26 (50) 3 (50) 0.665 (1s) 
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9 DISCUSSION 
 
The studies in the thesis have shown that there are great disparities in routines regarding AP 
in patients operated for gallstone disease. Whereas the risk for serious infectious complication 
may be reduced in selected high-risk patients, there is no need for the routine use of AP in 
gallstone surgery. Any decision to use AP must be weighed against the side-effects associated 
with uncritical widespread use of antibiotics. 
There is evidence that AP is beneficial during high-risk and contaminated procedures. This 
was confirmed in Study III. Gallstone surgery has generally been considered a contaminated 
procedure due to presumed bactibilia. Most elective surgery after a cholecystitis or episode of 
bile colic reveals no sign of inflammation or infection. The majority of studies performed, 
have not shown any benefit of AP in reducing PIC rates in elective cases. Studies on bile 
sampled intraoperatively using standardised methods have not shown a clear relationship 
between positive bile culture and the risk for PIC. Accordingly, the value of AP in surgery for 
mild to moderate cholecystitis should be questioned. There are reasons to believe that proper 
preoperative skin preparation and good surgical technique avoiding gallbladder perforation, is 
more effective in preventing surgical site infection than AP.   
There are still no generally accepted evidence-based guidelines on when to give AP. 
Furthermore, there is no consensus on whether to give a single dose, 3 doses or 5 doses. This 
is probably the reason behind the lack conformity between hospitals and between surgeons in 
Sweden regarding the use of prophylaxis, as seen in Study II. The results were adjusted for all 
relevant confounders that could possibly explain any difference in routines, but the difference 
remained statistically significant. There is a clear overuse of antibiotics in many situations, 
which may fuel the increase in antibiotic resistance. Even if the level antimicrobial drug 
resistance in Sweden is low, it is steadily increasing (67). Uncertainty, variation and overuse 
of AP exposes the patients to risk without scientifically proven benefit.  
The disparities shown in Study II probably reflect local and personal traditions. Over time 
such traditions may give a delusive feeling of following principles that are assumed to be 
established and based on evidence.  
The National Institute for Health and Care Excellence (NICE) aims at improving health and 
social care through evidence-based guidelines. NICE guidelines regarding prevention and 
treatment of SSI around skin incisions include evidence-based advice that may suitably be 
applied in the perioperative period (68). Although 11 years have passed since these guidelines 
were published, they are seldom adhered to by the surgeon despite the evidence in their 
favour (69). In one of the largest hospitals in Italy, adherence to international guidelines on 
AP regarding, duration, timing and type of antibiotic was only 48%. Prophylaxis was used in 
73% of procedures despite this not being recommended in current guidelines (70). It is the 
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responsibility of each hospital and surgeon to adhere to the evidence based international 
guidelines. 
It is the professional responsibility of every physician to limit the use of antimicrobial 
treatment, and to follow guidelines when prescribing them. This is an important part of all 
stewardship programmes and is necessary if we are to maximise clinical outcome and 
minimise the emergence of antimicrobial resistance (71). 
A Cochrane review published 2017 assessed the effectiveness of antibiotic stewardship 
interventions in hospital healthcare, and evaluated the impact of these interventions on 
compliance with antibiotic policy and reduction in duration of antibiotic treatment (72). The 
report suggested that stewardship interventions could be effective, particularly in terms of 
feedback to prescribers, in reducing length of hospital stay without endangering safety, 
duration of antibiotic treatment and excessive antibiotic prescribing to hospital inpatients.  
There is evidence that hospital-based programmes aimed at stricter routines for antibiotic use, 
may optimise the treatment of infections as well as reduce adverse events associated with 
antibiotic use (71). A Cochrane review of 89 studies showed that interventions to reduce 
antimicrobial prescription to inpatients may reduce drug-resistance and hospital-acquired 
infections and improve clinical outcome (73).  
The implementation of an effective antimicrobial stewardship programme, based on 
antimicrobial use and resistance patterns, may prevent antimicrobial resistance development 
and reduce the number of cases of Clostridium difficile diarrhea (74-76).  
In view of the continuing emergence of antibiotic resistance, developing new drugs that are 
based on the same pharmacological principles as drugs that are already established is not a 
sustainable strategy in the long run, particularly as antibiotics are difficult and costly to 
develop (77). At present there are no antibiotics in the pipeline that are effective against the 
most drug-resistant gram-negative organisms (78), and totally resistant Neisseria gonorrhoea 
is a typical example.  
Continual feedback, increased awareness of the surgeon, and repeated surveys may improve 
compliance to antimicrobial stewardship interventions (79). Furthermore, if antimicrobial 
stewardship is to be more convincing for practitioners, it needs to be widely understood that it 
is crucial for patient safety (77).   
STRAMA (Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and 
Surveillance of Resistance) was started in Sweden 1994 in order to provide surveillance of 
antibiotic use and resistance, to implement rational routines for use of antibiotics and provide 
us with new knowledge (67). The goals of STRAMA are to preserve the effectiveness of 
currently available antibiotics, to work for better basic hygiene precautions, and encourage 
more appropriate choice, dosage, and length of antibiotic treatments in Sweden (80). 
STRAMA has indeed played an important role in the reduction of antibiotic use in Sweden 
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(67, 79), but even so there is still considerable room for improvement as seen in the results of 
Study II regarding antibiotic usage.  
In Study III, we undertook unadjusted and adjusted analyses in order to assess patient-related 
factors that may have had an impact on the SSI and septicaemia.  The multivariate analyses 
included age >70 years, ASA class ≥2, indication for surgery (gallstone complication versus 
no complication), open surgery, duration of surgery >120 minutes and intraoperative 
antibiotics. These factors must be taken into consideration together with procedure-related 
risk factors when deciding on PAP. This study was based on a cohort from GallRiks, and we 
found a moderate impact of comorbidity on SSI and septicaemia. The comorbidities found to 
have the greatest impact were chronic kidney disease and cirrhosis when adjusting for other 
confounders (age, gender, ASA, indication for surgery, operation approach and time, 
antibiotic treatment and accidental gallbladder perforation). The risk for SSI was found to 
increase four- and five-fold in patients with these conditions respectively. The planning of 
any procedure in a patient with either of these risk factors should aim at minimising other 
factors that may affect outcome.  Postoperative care with resources for monitoring and 
frequent controls may reduce perioperative risks, as may AP, good surgical technique and 
experienced surgeons. Another study focusing on patient-related risk factors, including 
diabetes, obesity, smoking, malnutrition, steroid use, and immunosuppression showed a 
significant association between these factors and PIC (69). 
Obesity is a major health problem in many countries and an independent risk factor for SSI 
(81-83). This has also been confirmed in a recent study (84). 
Hyperglycaemia has been reported to increase the risk for SSI (85). Although we did not have 
any data on glucose levels in Study III, we did find an association between history of diabetes 
and the risk for SSI and septicaemia.   
The high OR for each comorbidity investigated suggests that AP should be considered in 
high-risk patients, even when risk factors related to the procedure per se are not anticipated.  
Smoking, nutrition status and grade of cholecystitis are also important confounders that we, 
unfortunately, were not able to adjust for based on data from the registers.   
Results from an RCT study including 166 patients did not show any reason to give AP to 
prevent SSI and abscess simply because bile spillage occurs during routine elective 
cholecystectomy  (86). The subgroup analyses in Study I regarding accidental gallbladder 
perforation during cholecystectomy did not show significant decrease in OR for PIC and 
abscess, not even when adjusting for all relevant confounders. Bile spillage, conversion to 
open surgery and ASA class >2 have been shown in a large prospective study, to be 
independent risk factors for SSI (87). In that study, patients received at least 1 dose of a 
second-generation cephalosporin, both acute and elective cholecystectomies were included, 
and no information was given about bile spillage.  
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NICE recommendations regarding SSI prevention is giving AP in clean surgery (i.e. no 
inflammation and without interference with sterile circumstances where respiratory, and 
where alimentary or genitourinary tracts are not entered) only in case of replacement of a 
prosthesis or implant, and to all clean-contaminated and contaminated procedures. 
Contaminated surgery includes acute cholecystectomy where there is mild degree non-
purulent inflammation of the gallbladder (GradeI) (68).  
The same advice is given in other guidelines, recommending AP in AC even when it is mild 
or moderate. These recommendations are probably based on safety assumptions and lack of 
scientific evidence against benefit from AP (TG18). To our knowledge, there is still no 
published study on randomised AP in acute cholecystectomy regarding the effect on PIC.  
Study I was a cohort study based on a database of 13,911 cholecystectomies registered 
between January 2006 and December 2010 in Sweden. The study showed no significant 
association between AP and PIC. Association between AP and PIC was adjusted for 
cofounders by stepwise inclusion. The OR decreased with each covariate added, but did not 
reach statistical significance. Subgroup analysis for AC, obstructive jaundice and gallbladder 
perforation also resulted in an OR that remained insignificant, even when adjusting for the 
confounders. The population Study I is of the largest yet published. Although the coverage of 
GallRiks is high, it is not 100%. Missing data and misclassification might have led to 
selection bias. The fact that only one randomised study has shown benefit of AP was one of 
the reasons for performing Study IV.  
Many studies and meta-analyses have reported no benefit of AP in elective laparoscopic 
cholecystectomy. Matsui performed a review of all RCTs included in 7 meta-analyses and 
calculated the pooled risk ratio and found that AP significantly reduces the risk for 
postoperative infection (42). In this review, they excluded 11 meta-analyses because of 
irrelevant content. The remaining studies all had RR overlapping 1 apart from their own 
study.  
On the other hand, four RCTs have recently been presented on the effects of postoperative 
AP versus placebo on the postoperative infection rate after acute cholecystectomy for mild to 
moderate cholecystitis.  In all of these studies the patients received PAP (≥ 1 dose). 
Postoperative complications ranged from (5.7 – 17%) (45-47, 88) and continued 
postoperative, AP gave no benefit compared to placebo. Based on the experience from these 
studies, the next step would be to conduct a RCT study with only preoperative AP or placebo. 
A few randomised trials comparing antibiotic with placebo in surgery for cholecystitis have 
been published. These studies were performed before the era of Lap-C, and although they 
showed some benefit from AP, the validity of these studies today is limited (89, 90). 
Conducting a similar trial today is difficult because of the complexity of the current 
healthcare system and is probably why there has not been a recent RCT study on AP in acute 
cholecystectomy. Study IV was a single-centre double-blinded randomised study conducted 
between 2009 and 2017.  
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The study showed, albeit without power sufficient to detect any minor reduction, no great 
impact on PIC rate and we concluded that the routine use of AP is questionable. The study 
population included Grades I and II cholecystitis according to the Tokyo guidelines, i.e. a 
group with a high risk for PIC. However, the latest Tokyo guidelines, 2018, recommend 
antibiotic treatment with type and duration depending on the severity of cholecystitis (30). 
The guidelines state that mild cholecystitis could be treated without AP, but give no clear 
criteria for patients requiring antibiotic treatment. Postoperative complications are 
multifactorial and AP does not provide the benefit expected. Bactibilia does not seem to be of 
predictive value for PIC (positive cultures were more frequent in the non-event group than in 
group with PIC), but CRP and method of approach had a significant impact on PIC in Study 
IV. Further studies with higher power are needed to confirm these results. 
When deciding on AP during acute cholecystectomy, patient- as well as procedure-related 
risk factors should be considered. These include severity of gallbladder inflammation, 
duration of symptoms, comorbidity, blood markers of infection and contamination level 
during the operation. Only then can we improve patient outcome and minimise the adverse 
effects of antibiotic treatment, both for the patient and society.   
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10 CONCLUSIONS 
 
I. Antibiotic prophylaxis has no significant impact on postoperative infectious 
complication rate in acute cholecystectomy. 
II. There is a disparity in routines regarding antibiotic prophylaxis during surgery for 
gallstone disease in Sweden. This is apparent at hospital and surgeon levels, but not at 
the county level. 
III. Patient-related risk factors have an impact on surgical site infection and septiceamia 
after surgery for acute cholecystitis. These factors should be taken into consideration 
when deciding on antibiotic prophylaxis. 
IV. Antibiotic prophylaxis does not have a significant impact on the risk for postoperative 
infectious complication and bactibilia in acute cholecystitis. 
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Gallstenar förekommer hos 10–20% av befolkningen. Av dessa utvecklar 20 % 
komplikationer i form av gallstensanfall, kolecystit (gallblåsinflammation), kolangit 
(gallgångs infektion) eller pankreatit (bukspottskörtelinflammation) någon gång under livet. 
Standardbehandlingen för patienter med gallsten och kolecystit, pankreatit eller gallstenskolik 
är att operera bort gallblåsan med dess innehåll av stenar med hjälp av laparoskopi 
(titthålsteknik), så kallad laparoskopisk kolecystektomi. Den första laparoskopiska 
kolecystektomin utfördes 1985 av den tyske kirurgen Mȕhe. Idag utförs upp till 95% av 
kolecystektomier laparoskopiskt, i de flesta fall utan betydande risker. Komplikationsrisken 
är som lägst på friska individer vars operation görs elektivt (planerad i lugnt skede) medan 
den ökar med graden av inflammation i gallblåsan, patientrelaterade riskfaktorer och andra 
operationsrelaterade riskfaktorer.  
Infektiösa komplikationer (IK) drabbar upp till 17% hos patienter med låg till moderat grad 
av kolecystit när de opereras akut. Länge har man trott att en dos av antibiotika som ges innan 
operationen (antibiotikaprofylax, AP) minskar risk for IK efter kolecystektomi. Denna 
princip har etablerat sig i dagens rutiner. Risken för IK är betydligt lägre vid planerade 
operationer, där studier har visat att antibiotikaprofylax inte har någon plats hos patienter med 
låg risk vid planerad kirurgi. Detta är dock inte studerat i situationer när operationen utförs i 
ett skede där man har inflammation och kanske infektion i gallblåsan. Vissa riskfaktorer som 
skulle kunna påverka IK risken är välkända och välstuderade. Riktlinjer på många håll är 
dock att man ordinerar antibiotikaprofylax vid alla akuta laparoskopiska kolecystektomier. 
Många rekommendationer är baserade på konsensus och inte på kliniska väl genomförda 
studier. Detta leder till överanvändning och felanvändning av antibiotika över hela världen 
med ökad risk för selektion av bakterier som är resistenta och spridning av dessa i en 
snabbare takt.  
Multiresistenta bakterier sprider sig allt mer i hela världen, särskilt där förskrivning av 
antibiotika är frikostig. Sverige har haft en låg nivå av multiresistenta bakterier sedan länge, 
även om den dock ökat långsamt. Idag har vi ett mycket begränsat urval av antibiotika som är 
effektiva och det finns inga nya antibiotika som förväntas komma i bruk inom den närmaste 
framtiden. Vi måste därför i våra rutiner begränsa användningen av de antibiotika som finns 
tillgängliga idag.  
I delarbete ett har vi hämtat information om patienter som genomgått akuta kolecystektomier 
mellan januari 2006 och december 2010 från det svenska kvalitetsregistret GallRiks med 
täckning upp till 85% av alla utförda kolecystektomier i Sverige. Totalt 13 911 patienter 
inkluderades i analysen, där AP gavs i 68,6% av ingreppen. Analyserna visade ingen skillnad 
mellan gruppen som fick AP jämfört med de som inte fick AP vad gäller IK när man tar 
hänsyn till de kända riskfaktorerna.  
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I det andra delarbetet studerade vi alla de 113 209 patienter som genomgått kolecystektomi 
registrerade i GallRiks mellan 2005–2015. Där såg man att rutiner för AP användning 
varierar signifikant mellan sjukhusen och kirurger men inte mellan landstingen i Sverige. 
Variationen berodde inte på typ av operation eller svårighetsgraden, utan lokala och 
personliga rutiner som påverkade valet.  
Vi undersökte också om patientrelaterade riskfaktorer påverkar risken för IK i tredje 
delarbetet. Information hämtades från GallRiks och matchades med Nationella 
patientregistret för de totalt 94 557 patienter som var registrerade mellan 2006–2016. När 
resultatet korrigerades för riskfaktorer som var relaterade till proceduren, fann vi att 
bindvävssjukdom, diabetes, njursvikt, skrumplever och övervikt var sjukdomar som 
påverkade risken för lokala infektioner efter operationen. Vi fann också att risken för 
blodförgiftningar och kolangit ökade och att patienter med njursvikt och skrumplever hade en 
tre respektive fem gånger ökad risk. En mindre riskökning sågs även hos de med 
bindvävssjukdom och diabetes.  
I det fjärde delarbetet, som var en dubbelblind randomiserad studie, ingick patienter med låg 
och mild kolecystit vilka randomiserades mellan att få antibiotika eller placebo 
(infusionslösning utan verksam substans) utan att varken patient, kirurg eller sjuksköterska 
visste vad patienten fick. Vi följde upp patienterna 30 dagar efter operationen för att 
registrera IK och återhämtningen. Incidensen av IK var något högre hos patienter som inte 
fick AP men resultatet var inte signifikant. Positiva odlingar från gallan i gallblåsan skiljde 
sig inte heller mellan grupperna. CRP (blodprov som stiger vid infektioner) var högre hos de 
som hade IK. Andelen operationen oftast konverterades till öppen teknik var fler hos 
patienter med IK.  
Sammanfattningsvis fann vi att AP inte har den förväntade och önskvärda effekten på IK hos 
patienter som opereras akut for kolecystit. Risken att på IK beror på många faktorer och 
patientens egna risker måste beaktas vid bedömning av risk för IK. Riktlinjer som är 
vetenskaplig välgrundade krävs för en enhetlig och tydlig regim för AP vid akuta 
laparoskopiska kolecystektomier.  
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